"Study of the Safety and Tolerability of the Broad-spectrum Probiotic Medicine AS-Probionorm"

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 2, 2023

Primary Completion Date

October 14, 2023

Study Completion Date

October 14, 2023

Conditions
Intestinal InfectionsDysbacteriosis
Interventions
DRUG

"AS-Probionorm"

"Dosage form - powder for the preparation of a solution for oral administration. Dosage regimen -1 sachet (1 g) take 2 times a day with an interval of 12 hours. Apply 15-20 minutes before meals in the morning and evening. Before use, the medicine is mixed with 30-50 ml of boiled water at room temperature, resulting in a cream-colored suspension. The resulting aqueous suspension should be drunk without achieving complete dissolution. The diluted drug cannot be stored. The duration of taking the medicine is 7 days. The study is carried out on an outpatient basis.~The total duration of each subject's participation in the clinical trial is no more than 21 ± 1 days. Throughout the entire study period, the research subject has the opportunity to contact the research team on all questions relating to the nature of this study. After completion of the entire observation period of 21 days, there is no follow-up of study subjects under the trial protocol."

Trial Locations (1)

Unknown

MIPO Clinic LLP, Almaty

All Listed Sponsors
lead

Industrial Microbiology LLP

OTHER

NCT06252831 - "Study of the Safety and Tolerability of the Broad-spectrum Probiotic Medicine AS-Probionorm" | Biotech Hunter | Biotech Hunter